Bayer beats expectations in 2nd-qtr results; raises guidance

27 July 2016

German pharma major Bayer (BAYN: DE) has beaten earnings expectations for 2016’s second quarter and increased its guidance for the year.

Across the group, earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for one-off items, rose by 5.7% compared to a year ago, to 3.05 billion euros ($3.35 billion), which is more than 5% above what many analysts had predicted.

Group net income was 1.38 billion euros, which is 18.6% higher than in the second quarter of 2015. Core earnings per share were 2.07 euros, a 4% increase on a year earlier, and sales grew by 2.3% to 11.83 billion euros ($13.01 billion) when accounting for currency and portfolio effects.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK